A5032773936- Adolescent and Pediatric Healthcare
- Autoimmune and Inflammatory Disorders Research
- Child and Adolescent Health
- Human Health and Disease
- Healthcare Systems and Public Health
- COVID-19 Clinical Research Studies
- Childhood Cancer Survivors' Quality of Life
- Immunodeficiency and Autoimmune Disorders
- Long-Term Effects of COVID-19
- Rheumatoid Arthritis Research and Therapies
- Family and Disability Support Research
- SARS-CoV-2 and COVID-19 Research
- Immune Cell Function and Interaction
- Musculoskeletal Disorders and Rehabilitation
In most cases, COVID-19 has a favorable outcome. However, the risk of developing critical forms disease, including secondary hemophagocytic lymphohistiocytosis HLH (cytokine storm syndrome), remains high. This dictates interest in studying pathogenetic mechanisms, features clinical picture, laboratory and instrumental criteria for covid-19 disease. The article analyzes causes acute respiratory distress syndrome multiple organ failure as manifestations HLH. necessity monitoring signs...
Rheumatic diseases (RD) are chronic, disabling, rapidly progressive immunoinflammatory that require careful monitoring of the patient's condition and timely administration targeted therapy. The rapid development science has made it possible to achieve significant achievements in treatment RD: increase frequency achieving remission disease, duration significantly improve quality life patients. information received from rheumatologists, who directly provide medical care patients with RD, is...
Juvenile arthritis with systemic onset (syn: juvenile idiopathic arthritis; SJIA) is the most complex in pathogenesis, severe course and unfavorable prognosis variant of arthritis. The SJIA characterized by development life-threatening complications, which future may lead to progression functional multiple organ failure, delayed physical disability patient, therefore it very important diagnose this disease at an early stage, for children suspicion must be examined accordance Procedure...
Rationale. Children with rheumatic diseases receiving immunosuppressants and/or genetically engineered biopharmaceutical drugs (GEBDs) glucocorticosteroids (GCs) are at high risk of developing severe long-term symptoms novel coronavirus infection. The possibilities pre-exposure prophylaxis COVID-19 in this patient population significantly limited due to the risks insufficient immunogenicity vaccine presence secondary immunodeficiency developed under conditions immunosuppressive therapy and...
The incidence of rheumatic diseases has been constantly growing during the last 20 years, which necessitates regular assessment healthcare quality for these patients and identification most significant problems ways to address them. Juvenile idiopathic arthritis (JIA) is one frequent disabling in children. prevalence JIA allow us use this disorder evaluate organization rheumatology care general terms its accessibility quality, as well measures improve it. This article reviews epidemiology,...
The survey of parents is one the optimal opportunities to understand drawbacks healthcare children with rheumatic diseases, since these are not reflected in patient medical records, statistical data, and opinion doctor. Parents surveys provide information on subjective understanding disease symptoms, duration characteristics child's route from onset diagnosis treatment initiation, choice primary care physician, problems route, awareness, legal field regulating diseases. Objective. To...
Juvenile arthritis (Syn.: Systemic adolescent idiopathic arthritis; hereinafter referred to as the JA, sJA) is most complex pathogenesis, severe process, and poorly predicted variant of arthritis. The characteristic sJA process development life-threatening complications, which may lead further functional multi organ failure, delayed physical development, patient disability. In this regard, it necessary diagnose disease correctly in early stages. Therefore, children suspected having should be...
Secondary hemophagocytic syndrome (SHS) is a life-threatening complication of systemic juvenile idiopathic arthritis (SJIA, syn.: systemic-onset arthritis). Timely treatment SHS can improve outcomes and reduce mortality rates. There has been little evidence worldwide on the effectiveness therapy for in patients with SJIA, including use genetically engineered biopharmaceutical drugs (GEBDs). Objective. To evaluate efficacy different regimens SJIA. Patients methods. This study included 100...
Background. Secondary hemophagocytic lymphohistiocytosis (sHLH) is a potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA) characterized by hyperinflammation and variety clinical laboratory manifestations. This condition also referred to as macrophage activation syndrome (MAS) in patients with rheumatic diseases, including those sJIA. In this article, we use the term sHLH. Approximately 40% sHLH cases are asymptomatic, especially who receive biologicals. Thus,...